DERMATOP® Emollient Cream (prednicarbate emollient cream) 0.1% contains prednicarbate, a synthetic corticosteroid for topical dermatologic use. Topical corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Each gram of DERMATOP Emollient Cream 0.1% contains 1.0 mg of prednicarbate.
DERMATOP Emollient Cream 0.1% is a medium-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. DERMATOP Emollient Cream 0.1% may be used with caution in pediatric patients 1 year of age or older. The safety and efficacy of drug use for longer than 3 weeks in this population have not been established. Since safety and efficacy of DERMATOP Emollient Cream 0.1% have not been established in pediatric patients below 1 year of age, its use in this age group is not recommended.
Media Articles Related to Dermatop ( Topical)
FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Source: MedicineNet brimonidine Specialty [2013.08.28]
Title: FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Category: Health News
Created: 8/27/2013 12:35:00 PM
Last Editorial Review: 8/28/2013 12:00:00 AM
Burn Risk Seen with Topical Pain Relievers
Source: MedPage Today Product Alert [2012.09.13]
WASHINGTON -- The FDA warned Thursday of the risks of rare but serious chemical burns with certain over-the-counter topical pain relievers, including Bengay, Capzasin, Flexall, Icy Hot, and Mentholatum.
Vitaros® (alprostadil), the first cream to treat men with erectile dysfunction, is now available for prescription in the UK
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2014.06.17]
The first topical cream approved for the treatment of erectile dysfunction (ED) in men over the age of 18 years, Vitaros® (topical alprostadil cream), is now available for prescription in the...
Published Studies Related to Dermatop ( Topical)
Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in
patients receiving botulinum toxin therapy. 
as a potential new therapy in BSP... CONCLUSIONS: Topical AH8 is safe and promising for
Instant dentin hypersensitivity relief of a single topical application of an
in-office desensitizing paste containing 8% arginine and calcium carbonate: A
split-mouth, randomized-controlled study. 
Abstract Objective. The aim of this study was to evaluate the clinical efficacy
of an in-office desensitizing paste containing 8% arginine and calcium carbonate
relative to calcium carbonate alone in the reduction of dentin hypersensitivity
in a randomized, double-blind, split-mouth clinical trial...
Effect of subgingival application of topical ozonated olive oil in the treatment
of chronic periodontitis: a randomized, controlled, double blind, clinical and
microbiological study. 
CONCLUSION: The OZO, as an adjunctive therapy as well as a mono-therapy is
Topical capsaicin (low concentration) for chronic neuropathic pain in adults. 
CONCLUSIONS: There were insufficient data to draw any conclusions about
Treatment for postoperative wound pain in gynecologic laparoscopic surgery:
topical lidocaine patches. 
CONCLUSIONS: Topical lidocaine patches at the laparoscopic port sites reduced
Clinical Trials Related to Dermatop ( Topical)
Standardized Time- and Score-Oriented Treatment of Moderate and Severe Atopic Dermatitis [Completed]
The study was designed to test the hypothesis whether a standardized, time-and score-oriented
treatment following a strict evidence based algorithm is equally effective to a standard
treatment regimen for moderate to severe atopic dermatitis.
Study Type: Mono-centre study, patients are blinded, physicians are randomized to either
treat study- or controll group
Eligible are patients age 2 years or older with SCORAD >= 20 Duration: 12 Months, study
visits every 4 weeks.
Primary endpoint is Difference between Baseline SCORAD and mean SCORAD under treatment.
Secundary endpoints are quality of life, safety and economic burden in both treatment
Fexofenadine in Pruritic Skin Disease [Completed]